OOIR: Observatory of International Research

Papers

(The H4-Index of European Journal of Clinical Pharmacology is 23. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-07-01 to 2026-07-01.)

Article	Citations
Might chronic spontaneous urticaria develop after SARS-CoV-2 vaccinations?	164
Oral Melatonin for Pain Relief During Venepuncture in Neonates– a Pilot Randomized Control Trial	78
How to make the best of NLRP3 inhibitors in patients with COVID-19?	70
A Study Of the effect of Sex on drug dosing, concentrations, and pharmacogenomics in the Montreal Heart Institute Hospital Cohort (SOS-PGx): methodology and research progress	53
Correction to: A real-world pharmacovigilance study of adverse events associated with esketamine: disproportionality analysis and detection of potential drug-drug interaction signals	43
Incidence and risk factors of drug-induced kidney injury in children: a systematic review and meta-analysis	40
Identification of novel signal of DRESS associated with antibiotics: a disproportionality analysis of the FDA adverse event reporting system (FAERS) database	39
Lowering cyclosporine trough concentration threshold effectively mitigates acute graft-versus-host disease in children with severe β-Thalassemia post hematopoietic stem cell transplantation	39
Usefulness of mirtazapine and SSRIs in late-life depression: post hoc analysis of the GUNDAM study	37
A systematic literature review of economic evaluations of setmelanotide	33
Population pharmacokinetics and pharmacodynamics of meropenem in critically ill patients with renal impairment or on continuous renal replacement therapy	33
Signal detection between 5-alpha reductase inhibitors and the risk of suicidality and depression: an international pharmacovigilance analysis	32
The Effect of the combination therapy of statin and dapagliflozin, a selective inhibitor of sodium_glucose Co-transporter type 2, in the treatment of Ischemic heart disease with heart failure: A rando	31
Beyond safety: adverse events and unanticipated advantages of SGLT2 inhibitors	30
Use of overactive bladder anticholinergic medications associated with falls leading to emergency department visits: results from the ADRED study	30
A phase 1 study in healthy participants to characterize the safety and pharmacology of inclacumab, a fully human anti-P-selectin antibody, in development for treatment of sickle cell disease	29
Understanding attitudes towards psychiatric medications: a comparative study of patients, healthcare professionals, and general population perspectives	29
The efficacy and safety of direct oral anticoagulants versus vitamin K antagonists in patients with left-sided bioprosthetic heart valves and atrial fibrillation: a systematic review and meta-analysis	27
Effects of sodium-glucose cotransporter 2 inhibitors on renal risk factors in patients with abnormal glucose metabolism: a meta-analysis of randomized controlled trials	27
Assessment of body mass-related covariates for rifampicin pharmacokinetics in healthy Caucasian volunteers	25
Comment on “Use of statins and risks of ovarian, uterine, and cervical diseases: a cohort study in the UK Biobank”	25
Economic evaluation of antibody-drug conjugates (ADCs) in patients with breast cancer: systematic review	23
Response to comment on “The role of prescribed opioids in Norwegian overdose deaths in 2005–2021”	23